Janet Pope Janetbirdope
1 month 3 weeks ago
#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming
➡️esp if multi drug failure already
By Hector Chinoy #WIN #IIM June5
Excellent #CAR-T review
should re think of
Total immune reset in many #SARD PTS is unlikely
EULAR2026 @RheumNow https://t.co/eqKzxzqa0z
Bella Mehta bella_mehta
1 month 3 weeks ago
Using AI to integrate EHR, SDOH , psychological data - can help finding psychosocial risk factors.
Complex cases can be diagnosed using solutions (iceberg health) like this. #EULAR2026 @rheumnow https://t.co/t4keRbpkrx
sheila RHEUMarampa
1 month 3 weeks ago
Not just ticking boxes!
Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA
What’s new?
Providing a stem so criteria will be applied only if w/SpA dx, not just imaging
MRI:active inflamm + structural lesions
Some SpA features omitted
@RheumNow #EULAR2026 https://t.co/NCV0EFvjYa
Janet Pope Janetbirdope
1 month 3 weeks ago
Can we have an effective, comprehensive score for
#SLE #arthritis?
#SLEDAI has a problem
SJC>2 scores dames as ex #SJC=12
Meet
#LAMBDA
An attempt to improve a true positive #MSK OUTCOME in #lupus
Needs validation esp in pts over time
#EULAR2026 @RheumNow #POS1072
@eular_org https://t.co/fr0xuVqFnM
Antoni Chan MD (Prof) synovialjoints
1 month 3 weeks ago
Large French nationwide cohort (n=56,591 SpA patients) showed that >6 months/year of targeted therapy exposure was associated with reduced overall cancer risk (wHR 0.86), especially for haematological malignancies (wHR 0.65). Reassuring long-term safety signal. Abstr OP0238
Jiha Lee JihaRheum
1 month 3 weeks ago
Not all #RA pts respond equally to advanced therapy. 10-variable risk model >18k US pts: low baseline disease activity, fewer comorbidities, and no prior biologics 5x more likely to achieve remission at 1yr (34% vs 7%). RWD for precision care @RheumNow #EULAR2026 POS0257
Jiha Lee JihaRheum
1 month 3 weeks ago
Oral TYK2i deucravacitinib works for #PsA with OR without methotrexate. Pooled POETYK data (n=648): ACR20/50/MDA, enthesitis, dactylitis, skin responses, and PROs all comparable regardless of MTX use at wk 52. Good news for pts who can't tolerate MTX. @RheumNow #EULAR2026 POS0288
Antoni Chan MD (Prof) synovialjoints
1 month 3 weeks ago
The axSpA classification has been revised with the 2025 ASAS SPARTAN criteria. 5 abstracts at #EULAR2026 Abstr OP0236, OP0100, OP0239, POS0190 and POS1341.
The single most important change in the 2025 criteria: MRI is now the highest-weighted variable and what counts as a https://t.co/xg4R4xRH2D
Bella Mehta bella_mehta
1 month 3 weeks ago
AI use in rheumatology is probably going to be used the first in musculoskeletal imaging. Since patients journey is digitalised.
#EULAR2026 @RheumNow
We are drowning in healthcare data. https://t.co/61HqtSCQxC
Janet Pope Janetbirdope
1 month 3 weeks ago
+#RCT in #dermatomyositis with #brepocitinib
Oral #TYK2/JAK1i
241 pts
+outcomes
#TIS total improvement score
>40%TIS 68% v 44%
#steroid tapering
#skin improved rapidly #CLASI
#OP0166
#POS0264 @RheumNow #EULAR2026 https://t.co/9WZl9RsXXe
Md Yuzaiful Md Yusof Yuz6Yusof
1 month 3 weeks ago
#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac
There are so many SLE trials, and over the last year, many new ideas have been suggested.
Bella Mehta bella_mehta
1 month 3 weeks ago
Digitalization in rheumatology.
How can it help?
Potential opportunities
@RheumNow #EULAR2026 https://t.co/KKImSNLgbq
Jiha Lee JihaRheum
1 month 3 weeks ago
Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251
